The use of 3D printing prior to transaortic valve replacement (TAVR) procedures may help cardiac surgeons to predict areas where an ill-fitting stent frame could lead to paravalvular leaks (PVLs), a small retrospective study has shown.
Neither intravenous (IV) sodium bicarbonate nor oral N-acetylcysteine (NAC) is better than IV saline in reducing 90-day events or contrast-associated acute kidney injury (AKI) in the PRESERVE substudy, suggesting that normal saline hydration is the default therapy for contrast-induced AKI.
The hybrid approach to percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) yielded good success rates in the hands of experienced operators, the PROGRESS CTO* Registry study has shown, offering important benchmarking for discussion of the risk-benefit ratio of CTO PCI.
Transcatheter mitral valve repair with the MitraClip device significantly improves the severity of mitral regurgitation (MR), functional status, and quality of life of patients with MR and who were at prohibitive risk for surgery, according to the MitraClip Post-Approval Study 1 (PAS1) presented at SCAI 2018.
Biologic therapy for treating psoriasis, in particular anti-TNF agents, can also help reduce coronary plaque besides suppressing inflammation in the skin, suggests a study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions in San Diego, California, US.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Cardiology - Malaysia digital copy today!
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.